This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ALADIN | |
|---|---|
| Name | ALADIN |
| Caption | ALADIN protein structure (schematic) |
| Species | Homo sapiens |
ALADIN is a human nucleoporin implicated in nucleocytoplasmic transport, cellular oxidative homeostasis, and adrenal and neurological phenotypes. First characterized through clinical syndromic descriptions, ALADIN has since been studied in cellular, genetic, and model organism contexts that connect it to nuclear pore complex composition, protein trafficking, and stress response pathways.
ALADIN was identified in relation to a multisystem disorder involving Adrenal insufficiency, Achalasia, and Alacrima, linking it to defects in the nuclear pore complex and nuclear-cytoplasmic transport. Studies in patients and laboratories involving institutions such as the National Institutes of Health, University of Helsinki, and Max Planck Society tied ALADIN to the AAAS gene product and to phenotypes affecting the endocrine system, autonomic nervous system, and central nervous system. Work involving collaborations with researchers at Harvard Medical School, University of Oxford, and University College London broadened understanding of its role in human disease and cell biology.
The protein is encoded by the gene AAAS, historically named after the clinical triad described by clinicians at tertiary centers including Mayo Clinic and Great Ormond Street Hospital. The ALADIN acronym derives from the clinical constellation recognized in case series from teams at Finnish hospitals and international consortia led by investigators at Karolinska Institutet and INSERM. The gene symbol AAAS appears in databases curated by organizations such as the HUGO Gene Nomenclature Committee and is cross-referenced across resources produced by Ensembl, UniProt, and OMIM.
ALADIN is a peripheral component of the nuclear pore complex localized to the nuclear envelope; structural mapping used techniques developed at facilities like the European Molecular Biology Laboratory and the Max Planck Institute for Molecular Cell Biology and Genetics. Electron microscopy studies leveraging methods from groups at Johns Hopkins University and Massachusetts Institute of Technology positioned ALADIN at the nucleoplasmic face of the pore, influencing docking of transport factors such as members of the karyopherin family studied in laboratories at EMBL-EBI and Cold Spring Harbor Laboratory. Functional assays performed in cell lines distributed by repositories like ATCC and analyzed with tools from Broad Institute and Wellcome Sanger Institute linked ALADIN to selective permeability and quality control at the nuclear basket, interacting indirectly with structural nucleoporins characterized by teams at ETH Zurich and University of Geneva.
Loss-of-function variants in AAAS produce a syndrome recognized in clinical genetics clinics at centers such as Johns Hopkins Hospital and Boston Children's Hospital and described in case reports from investigators at Helsinki University Central Hospital and Karolinska University Hospital. Phenotypic manifestations include primary adrenal insufficiency managed by protocols from Endocrine Society guidelines and neuromotor deficits evaluated in neurology clinics at Mayo Clinic and UCSF Medical Center. Ophthalmological signs such as alacrima are managed in specialty centers including Massachusetts Eye and Ear; gastrointestinal dysmotility like achalasia is treated in surgical units at Cleveland Clinic and Mount Sinai Health System. Genotype-phenotype correlations have been reported in cohorts assembled by consortia involving International Rare Diseases Research Consortium partners and clinical registries curated by Orphanet.
AAAS resides on human chromosome 12 and has been sequenced and annotated in reference genomes provided by GRCh38 and projects like the 1000 Genomes Project and Exome Aggregation Consortium. Pathogenic variants include nonsense, frameshift, and missense alleles cataloged in variant databases coordinated by ClinVar and HGMD. Transcript expression profiling using platforms developed by Illumina and Affymetrix and single-cell atlases from projects like the Human Cell Atlas mapped AAAS expression across tissues including adrenal cortex samples from biobanks affiliated with UK Biobank and FinnGen. Molecular studies leveraging CRISPR technologies from groups at Broad Institute and MIT generated cellular knockouts to probe consequences on nucleocytoplasmic transport, redox-sensitive transcription factors characterized by laboratories at University of California, San Diego and Stanford University.
Biochemical and proteomic screens performed using mass spectrometry platforms at ProteomicsDB and techniques refined at European Proteomics Facility identified ALADIN-associated partners including nucleoporins studied at Yale University and transport receptors characterized by teams at Institut Pasteur. Signaling pathways influenced by ALADIN intersect with oxidative stress regulators such as NRF2 pathways researched at University of Cambridge and Johns Hopkins University, and with DNA damage response elements investigated at Salk Institute and Cold Spring Harbor Laboratory. Cellular models implicated ALADIN in modulation of steroidogenesis pathways evaluated by endocrine research groups at Karolinska Institutet and University of California, Los Angeles and in vesicular trafficking routes examined by researchers at University of Virginia and University of Pennsylvania.
Model organisms used to study ALADIN include zebrafish lines generated at facilities like Zebrafish International Resource Center and mouse models developed by transgenic groups at Jackson Laboratory and European Mouse Mutant Archive. Drosophila and C. elegans ortholog studies performed in laboratories at University of Cambridge and Max Planck Institute for Developmental Biology provided comparative insights into nuclear pore biology. High-content imaging and live-cell transport assays applied in collaborations involving Helmholtz Association and Riken have been used to probe dynamic defects. Ongoing research funded by agencies including National Institutes of Health, European Research Council, and Wellcome Trust focuses on therapeutic strategies encompassing gene therapy approaches investigated at NIH Clinical Center and small-molecule screens run in screening centers associated with EMBL and the Broad Institute.
Category:Human proteins